165 related articles for article (PubMed ID: 24428087)
1. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
Worasethsin P; Narkwichean A
J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
[TBL] [Abstract][Full Text] [Related]
2. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
3. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses.
Amirkhosravi A; Bigsby G; Desai H; Rivera-Amaya M; Coll E; Robles-Carrillo L; Faust P; Waters A; Meyer T; Reyes E; Langer F; Francis JL
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):510-7. PubMed ID: 23406663
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.
Van Calster B; Valentin L; Van Holsbeke C; Zhang J; Jurkovic D; Lissoni AA; Testa AC; Czekierdowski A; Fischerová D; Domali E; Van de Putte G; Vergote I; Van Huffel S; Bourne T; Timmerman D
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2420-8. PubMed ID: 21908724
[TBL] [Abstract][Full Text] [Related]
5. [The role of D-dimer in diagnosis of ovarian cancer].
Kanayama N
Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):485-8. PubMed ID: 2056222
[TBL] [Abstract][Full Text] [Related]
6. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF
Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712
[TBL] [Abstract][Full Text] [Related]
7. The risk of malignancy index in discrimination of adnexal masses.
Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a model that includes two ultrasound parameters and the plasma D-dimer level for predicting malignancy in adnexal masses: an observational study.
Stukan M; Badocha M; Ratajczak K
BMC Cancer; 2019 Jun; 19(1):564. PubMed ID: 31185938
[TBL] [Abstract][Full Text] [Related]
9. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
10. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
Holcomb K; Vucetic Z; Miller MC; Knapp RC
Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
[TBL] [Abstract][Full Text] [Related]
11. [Adnexal masses management: a prospective multicentric observational study].
Huchon C; Bats AS; Bensaïd C; Junger M; Nos C; Chatellier G; Lécuru F
Gynecol Obstet Fertil; 2008 Nov; 36(11):1084-90. PubMed ID: 18964176
[TBL] [Abstract][Full Text] [Related]
12. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Facchini V; Genazzani AR
Anticancer Res; 1995; 15(6B):2683-6. PubMed ID: 8669847
[TBL] [Abstract][Full Text] [Related]
13. Introduction of new Tumor Marker Age Score in clinical practice: Validity evaluation for differentiation benign from malignant adnexal masses.
Ladjević IL; Terzić M; Ladjević N; Dotlić J; Pilić I; Bila J; Knezević N; Milenković S; Maricić S; Arsenović N; Brndusić N; Nikolić B
Acta Chir Iugosl; 2012; 59(3):49-56. PubMed ID: 23654006
[TBL] [Abstract][Full Text] [Related]
14. The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.
Dolgun ZN; Kabaca C; Karateke A; İyibozkurt C; İnan C; Altıntaş AS; Karadağ C
Balkan Med J; 2017 Apr; 34(2):156-162. PubMed ID: 28418343
[TBL] [Abstract][Full Text] [Related]
15. The impact of size of the adnexal mass on the accuracy of frozen section diagnosis.
Geomini PM; Zuurendonk LD; Bremer GL; de Graaff J; Kruitwagen RF; Mol BW
Gynecol Oncol; 2005 Nov; 99(2):362-6. PubMed ID: 16051343
[TBL] [Abstract][Full Text] [Related]
16. Should cut-off values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?
Yavuzcan A; Caglar M; Ozgu E; Ustun Y; Dilbaz S; Ozdemir I; Yildiz E; Gungor T; Kumru S
Asian Pac J Cancer Prev; 2013; 14(9):5455-9. PubMed ID: 24175841
[TBL] [Abstract][Full Text] [Related]
17. [Application values of four risk of malignancy indices in the preoperative evaluation of patients with adnexal masses].
Lou HY; Meng H; Zhu QL; Zhang Q; Jiang YX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Jun; 32(3):297-302. PubMed ID: 20602883
[TBL] [Abstract][Full Text] [Related]
18. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses.
van den Akker PA; Aalders AL; Snijders MP; Kluivers KB; Samlal RA; Vollebergh JH; Massuger LF
Gynecol Oncol; 2010 Mar; 116(3):384-8. PubMed ID: 19959215
[TBL] [Abstract][Full Text] [Related]
20. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses.
Andersen ES; Knudsen A; Rix P; Johansen B
Gynecol Oncol; 2003 Jul; 90(1):109-12. PubMed ID: 12821350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
